EFFECT ·Filed Jun 9, 2026

CGEN

COMPUGEN LTD
NEUTRAL
Impact 3/10
Horizonweeks Processed3mo ago SEC9999999995-26-001920
IPO/offering going effective
Actionable Insight • Neutral

Monitor for any subsequent prospectus supplement or takedown announcement, which would reveal the size and pricing of an actual offering. The shelf's effectiveness itself is a routine procedural step, but the overhang may weigh on the stock until the company signals its intentions.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
CGEN ▲ +30.20% at T+60d
NEUTRAL call ✓ call won +30.20% · α vs SPY +26.38% · entry $2.02 → $2.63
Entry anchored
Jun 8, 03:59 PM ET
via exchange tick
T+1d
-2.97%
call -2.97% · α -1.39%
$1.96
settled 4mo ago
T+5d
0.00%
call 0.00% · α -2.41%
$2.02
settled 4mo ago
T+20d
+18.32%
call +18.32% · α +16.87%
$2.39
settled 3mo ago
T+60d
+30.20%
call +30.20% · α +26.38%
$2.63
settled 29d ago

Price Chart

Loading chart...

Executive Summary

Compugen's shelf registration statement on Form F-3 (File No. 333-295989) was declared effective by the SEC on June 8, 2026. This allows the company to offer and sell securities, including common shares, from time to time at its discretion, creating a potential dilution overhang for existing shareholders.

Key Facts

  • Shelf registration on Form F-3 (File No. 333-295989) declared effective on June 8, 2026.
  • Company can now offer and sell securities (e.g., common shares) at any time without further SEC review.
  • No specific offering size, pricing, or timing was disclosed in the effectiveness notice.

Financial Impact

No dollar amount disclosed; potential dilution from future offerings is indeterminate.

dilutionshare count

Risk Factors

  • Future share issuance could dilute existing holders.
  • Uncertainty about the timing and size of any offering may create overhang.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001920
Document: 9999999995-26-001920-index.html9999999995-26-001920
Document: 9999999995-26-001920.txt9999999995-26-001920
8 reports for CGEN
Performance horizon
Filters
Rows
Reports for CGEN — sortable, filterable
TypeNow
Aug 3, 2026
8w ago
6-K
NEUTRAL ★ 2/10
$2.38 $2.56▲ +7.56%▲ +6.33%$2.31 (−2.94%)
Aug 3, 2026
8w ago
6-K
NEUTRAL ★ 4/10
$2.38 $2.56▲ +7.56%▲ +6.33%$2.31 (−2.94%)
Jun 9, 2026
16w ago
EFFECT
NEUTRAL ★ 3/10
$2.02 $2.39▲ +18.32%▲ +16.87%$2.31 (+14.36%)
May 18, 2026
19w ago
6-K
NEUTRAL ★ 4/10
$2.86 $2.03▼ −29.02%▼ −30.60%$2.31 (−19.23%)
Apr 24, 2026
23w ago
Insider Cluster
NEUTRAL ★ 2/10
$3.10 $2.61▼ −15.81%▼ −19.83%$2.31 (−25.48%)
Apr 14, 2026
24w ago
Insider Cluster
NEUTRAL ★ 2/10
$2.88 $2.87▼ −0.35%▼ −6.64%$2.31 (−19.79%)
Apr 13, 2026
24w ago
144
NEUTRAL ★ 3/10
$2.76 $2.87▲ +3.99%▼ −3.74%$2.31 (−16.30%)
Mar 26, 2026
27w ago
Insider Cluster
NEUTRAL ★ 3/10
$2.06 $3.10▲ +50.49%▲ +39.82%$2.31 (+12.14%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (39h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access